Lupin Pharma Canada Announces Partnership with Endoceutics for the Commercialization of INTRAROSA®

March 8, 2021

Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, today announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize INTRAROSA® in Canada.

ENDOCEUTICS ANNOUNCES ACQUISITION OF THE INTRAROSA® U.S. COMMERCIAL RIGHTS BY MILLICENT PHARMA

May 27, 2020

Quebec City, Canada; Endoceutics announces that the U.S. commercial rights for its flagship product, INTRAROSA®, were transferred to Millicent Pharma following a divestiture process announced in January 2020 by AMAG Pharmaceuticals.

ENDOCEUTICS RECEIVES HEALTH CANADA APPROVAL FOR INTRAROSA

November 6, 2019

Quebec City, Canada; Endoceutics is happy to announce the approval of INTRAROSA by Health Canada for the treatment of postmenopausal vulvovaginal atrophy.

Endoceutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

April 25, 2019

Québec City, Canada; Endoceutics announced today that Dennis Turpin, President and Chief Executive Officer of Endoceutics, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference.

Endoceutics, Université Laval, and CHU de Québec settle their disputes

March 27, 2019

Québec City, Canada, March 27, 2019 – Endoceutics Inc., Université Laval, and CHU de Québec-Université Laval (CHU de Québec-UL) are pleased to announce that they have reached an agreement to resolve all their disputes with respect to economic benefits deriving from research. Université Laval and CHU de Québec-UL will share in the anticipated economic benefits associated with Intrarosa™.

Death of Dr. Fernand Labrie

January 17, 2019

Quebec City, January 17, 2019 – It is with great sadness that Endoceutics management announces the death of its president and founder Dr. Fernand Labrie at the age of 81.

HSDD publicity

February 22, 2018
September 26, 2017

2017 Galien USA Awards

July 12, 2017